Alice Bernier
Overview
Explore the profile of Alice Bernier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
117
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang Z, Xu X, Silva C, Farnos O, Venereo-Sanchez A, Toussaint C, et al.
Vaccines (Basel)
. 2022 Aug;
10(8).
PMID: 36016198
New influenza strains are constantly emerging, causing seasonal epidemics and raising concerns to the risk of a new global pandemic. Since vaccination is an effective method to prevent the spread...
2.
Gonzalez-Dominguez I, Lorenzo E, Bernier A, Cervera L, Godia F, Kamen A
Vaccines (Basel)
. 2021 Oct;
9(10).
PMID: 34696262
Gag-based virus-like particles (VLPs) have high potential as scaffolds for the development of chimeric vaccines and delivery strategies. The production of purified preparations that can be preserved independently from cold...
3.
Joshi P, Bernier A, Moco P, Schrag J, Chahal P, Kamen A
Mol Ther Methods Clin Dev
. 2021 Apr;
21:341-356.
PMID: 33898632
Removal of empty capsids from adeno-associated virus (AAV) manufacturing lots remains a critical step in the downstream processing of AAV clinical-grade batches. Because of similar physico-chemical characteristics, the AAV capsid...
4.
Joshi P, Bernier A, Chahal P, Kamen A
Hum Gene Ther
. 2021 Apr;
32(21-22):1390-1402.
PMID: 33860673
The development of various manufacturing platforms and analytical technologies has substantially contributed to successfully translating the recombinant adeno-associated viral vector from the laboratory to the clinic. The active deployment of...
5.
Farnos O, Gelaye E, Trabelsi K, Bernier A, Subramani K, Kallel H, et al.
Vaccines (Basel)
. 2020 Jul;
8(2).
PMID: 32604755
Developing vaccine technology platforms to respond to pandemic threats or zoonotic diseases is a worldwide high priority. The risk of infectious diseases transmitted from wildlife and domestic animals to humans...
6.
Manceur A, Kim H, Misic V, Andreev N, Dorion-Thibaudeau J, Lanthier S, et al.
Hum Gene Ther Methods
. 2017 Aug;
28(6):330-339.
PMID: 28826344
Lentiviral vectors (LV) represent a key tool for gene and cell therapy applications. The production of these vectors in sufficient quantities for clinical applications remains a hurdle, prompting the field...
7.
Shen C, Jacob D, Zhu T, Bernier A, Shao Z, Yu X, et al.
Vaccine
. 2016 May;
34(29):3381-7.
PMID: 27154390
Tuberculosis (TB) is the second leading cause of death by infectious disease worldwide. The only available TB vaccine is the Bacille Calmette-Guerin (BCG). However, parenterally administered Mycobacterium bovis BCG vaccine...
8.
Gilbert R, Guilbault C, Gagnon D, Bernier A, Bourget L, Elahi S, et al.
J Virol Methods
. 2014 Aug;
208:177-88.
PMID: 25159033
E1-deleted adenovirus vectors (AdV) are important gene transfer vehicles for gene therapy and vaccination. Amplification of AdV must take place in cells that express the adenovirus E1A and E1B genes....
9.
Michaud F, Havugimana P, Duchesne C, Sanschagrin F, Bernier A, Levesque R, et al.
Appl Biochem Biotechnol
. 2012 May;
167(3):474-88.
PMID: 22562494
Liquid chromatography mass spectrometry (LCMS) is a powerful technique that could serve to rapidly characterize cell culture protein expression profile and be used as a process monitoring and control tool....
10.
Dormond E, Chahal P, Bernier A, Tran R, Perrier M, Kamen A
J Virol Methods
. 2010 Feb;
165(1):83-9.
PMID: 20116403
The preparation of large amount of purified helper-dependent adenoviral vector material is hampered by the lack of development of downstream processes with proven records on separation and recovery efficiencies. In...